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In Brief
Lack of preventive therapies for common disorders of the nervous system constitutes a major unmet medical need. Gu et al. report a novel strategy targeting receptor tyrosine kinase signaling and identify a therapeutic for prevention of temporal lobe epilepsy.
INTRODUCTION
The epilepsies constitute a group of common, serious neurological disorders, among which temporal lobe epilepsy (TLE) is the most prevalent and is often devastating both because of its resistance to anticonvulsants and its associated behavioral disorders (Engel et al., 1998) . Many patients with severe TLE experienced an episode of continuous seizure activity (status epilepticus [SE] ) years prior to the onset of TLE (French et al., 1993) . Because induction of SE alone is sufficient to induce TLE in diverse mammalian species (Pitkä nen, 2010) , the occurrence of de novo SE is thought to contribute to development of TLE in humans.
Elucidating the molecular mechanisms by which an episode of SE induces lifelong TLE in an animal model will hopefully provide targets for preventive or disease-modifying therapies (Lö scher et al., 2013) . Recent work identified a molecular mechanism required for induction of TLE by an episode of SE, namely, the excessive activation of a receptor tyrosine kinase (RTK), TrkB (Liu et al., 2013) . A chemical-genetic method (Chen et al., 2005 ) was used to demonstrate that inhibition of TrkB signaling, initiated following SE and continued for 2 weeks, prevented both SE-induced TLE and anxiety-like behavior when tested 1 to 2 months after SE (Liu et al., 2013) . The objective of the present work was to seek an inhibitor of TrkB signaling for prevention of epilepsy caused by SE. We report a novel strategy for inhibition of RTK signaling in vivo in which we identify the dominant effector by which TrkB activation promotes its epileptogenic consequences and demonstrate therapeutic effects of a unique peptide that uncouples TrkB from this effector while sparing neuroprotective effects of TrkB signaling.
RESULTS

Inhibition of TrkB Kinase Exacerbates SE-Induced Neuronal Degeneration
Although our prior work advanced TrkB kinase as a therapeutic target for prevention of SE-induced TLE (Liu et al., 2013) , the pro-survival effects of TrkB signaling (Alcá ntara et al., 1997; Atwal et al., 2000) raised concern that inhibition of TrkB kinase might exacerbate SE-induced death of neurons (Henshall and Meldrum, 2012) . To address this issue, we used Fluro-Jade C (FJC) staining of hippocampal sections from mice euthanized 24 hr after SE to quantify neuronal degeneration (Mouri et al., 2008) . These experiments utilized a chemical-genetic method whereby administration of a small molecule, 1NMPP1, selectively inhibits TrkB kinase in TrkB F616A but not wild-type (WT) mice ( Figure 1A ) (Chen et al., 2005) . SE preferentially destroyed CA3 pyramidal cells as evident by FJC staining in sections from both WT and TrkB F616A animals treated with vehicle (Figures 1B and 1C) , confirming results of Mouri et al. (2008) . Using doses demonstrated to inhibit SE-induced activation of TrkB (Liu et al., 2013) , 1NMPP1 treatment of TrkB F616A mice produced 3-to 10-fold increases in the number of FJC-positive cells in the CA3 and CA1 pyramidal cell layers of hippocampus in comparison to vehicle treated controls ( Figures 1B and 1C) . Importantly, treatment of WT animals with 1NMPP1 after induction of SE produced no significant differences from vehicle ( Figure 1C ). In sum, these results demonstrate neuroprotective effects of TrkB kinase evident 1 day after SE and reveal a deleterious consequence of global inhibition of TrkB signaling in this context, namely exacerbation of neuronal degeneration.
Antiseizure Effect of Limiting Phospholipase Cg1 Signaling
The untoward consequences of global inhibition of TrkB kinase led us to seek the signaling pathway by which SE-induced activation of TrkB promotes epilepsy. That is, if the downstream pathways mediating the deleterious and beneficial effects of TrkB signaling induced by SE were distinct, then selective inhibition of the deleterious pathway could be an attractive strategy for drug development. To begin to elucidate the signaling pathways underlying the anti-epileptic consequences of TrkB kinase inhibition, we asked whether inhibition of TrkB-mediated activation of phospholipase Cg1 (PLCg1) might inhibit seizures evoked by microinfusion of kainic acid (KA) into the amygdala of adult mice (Figures 2A and 2B ). We initially studied TrkB PLC/PLC mice in which a phenylalanine is substituted for tyrosine at residue 816 of TrkB, thereby disrupting TrkB-mediated PLCg1 signaling (Minichiello et al., 2002 , n = 4). Data are presented as mean ± SEM and analyzed using two-way ANOVA with post hoc Bonferroni's tests, ***p < 0.001. (He et al., 2014; Ji et al., 1997) . Infusion of KA induced prolonged electrographic and convulsive motor seizures in each WT control mouse ( Figures 2F, 2G , and S1D-S1F). By comparison, the electrographic and convulsive motor seizures evoked by KA were reduced by 65%-70% in PLCg1 +/À mice ( Figures 2F, 2G , and S1D-S1F). Thus, the dominant mechanism underlying the antiseizure effects of the TrkB PLC/PLC mutation involves inhibition of PLCg1 activation, thereby providing the rationale for identifying compounds that selectively uncouple PLCg1 from activated TrkB.
pY816 Peptide Inhibits BDNF-Mediated Activation of PLCg1
This led us to design a membrane-permeable peptide comprising HIV-1 Tat protein transduction domain and a sequence of TrkB that is required for binding of PLCg1 to the motif of TrkB containing tyrosine 816 (pY816, YGRKKRRQRRRLQNLAKASPVpYLDI) (Middlemas et al., 1994; Obermeier et al., 1993 ). An HIV-1 Tat conjugated to a randomly scrambled peptide (Scr, YGRKKRRQRRR-LYApYQLKIAPNDLS) served as a negative control. We first examined the concentration dependence and time course of pY816-mediated inhibition of TrkBmediated PLCg1 activation in cultured neurons in vitro. Preincubation of pY816 for 90 min prior to addition of BDNF produced a concentration-dependent inhibition of BDNF-mediated PLCg1 activation ( Figures 3A and S2A ). Preincubation of pY816 at 10 mM for 60, 90, or 120 min prior to addition of BDNF produced marked inhibition of BDNF-mediated PLCg1 activation (Figures 3B and S2B) . Importantly, pY816-mediated inhibition was selective to PLCg1 in that BDNF-mediated increases of p-Akt and p-ERK were not affected (Figures 3A and 3B, rows 3 and 5) . With respect to in vivo actions, systemic infusion of pY816 reduced p-PLCg1 (pY783) immunoreactivity by $50% in comparison to Scr control at 3 hr ( Figure 3C ), and its inhibitory effects had dissipated at 72 hr as revealed by western blots of hippocampal lysates ( Figure S2C ). The reduction of p-PLCg1 (pY783) immunoreactivity was paralleled by a reduction of p-CaMKII immunoreactivity ( Figures 3C and S2D ), the predicted consequence of inhibiting TrkB-mediated activation of PLCg1 (Blanquet and Lamour, 1997; Minichiello et al., 2002) . Again the effects of pY816 were selective for PLCg1 in that neither p-Akt nor p-S6 nor p-ERK was affected ( Figure 3C , rows 5, 7, and 9). The inhibition of p-PLCg1 immunoreactivity is likely due to pY816 binding PLCg1 directly because PLCg1 can be coimmunoprecipitated with pY816 in hippocampus following systemic infusion of pY816 (10 mg/kg, 3 hr) ( Figure S3A ). The binding of PLCg1 by pY816 uncouples TrkB from PLCg1 because systemic infusion of pY816 (10 mg/kg) significantly inhibited the co-immunoprecipitation of TrkB and PLCg1 at 3 hr after peptide administration ( Figure 3D ). While pY816 may inhibit the interaction of PLCg1 with other RTKs in addition to TrkB, the principal RTK of its inhibition in this model is TrkB because inhibition of TrkB kinase virtually eliminated PLCg1 activation following SE ( Figure S3B ). Collectively, these experiments support the conclusion that pY816 selectively inhibits the activation of PLCg1 by TrkB following SE in vivo. (C) Scr or pY816 (10 mg/kg, i.v.) was injected into naive mice (n = 4) and animals were euthanized 3 hr later and hippocampal homogenates subjected to SDS-PAGE and western blotting. Compared to scrambled control peptide, pY816 peptide (10 mg/kg) reduces p-PLCg1 (pY783) and p-CaMKII (pT286) but not p-Akt, p-S6 or p-ERK immunoreactivity.
(D) Systemic infusion of pY816 peptide (10 mg/kg, i.v.) reduces co-immunoprecipitation of PLCg1 with TrkB compared to Scr control in hippocampal homogenates isolated 3 hr after infusion (n = 11 each).
(E-H) Systemic administration of pY816 at various doses (E and F, n = 3-4) or at various intervals (G and H, n = 3-4) prior to induction of seizures by infusion of KA into amygdala. Average EEG power normalized to baseline (E and G) and average behavioral seizure scores (F and H) were analyzed during 45 min after KA infusion. Scr-treated controls were included in experiments examining effects of doses (total of 10, E and F) and time (total of 18, G and H). Data are presented as mean ± SEM and analyzed using Student's t test (D) or two-way ANOVA with post hoc Bonferroni's test (E and G) or from individual animals as well as median and analyzed using Kruskal-Wallis test followed by Dunn's multiple comparisons test (F and H); *p < 0.05 and **p < 0.01.
pY816 Peptide Inhibits Chemoconvulsant-Induced Seizures
The genetic evidence that uncoupling TrkB from PLCg1 exerts antiseizure effects together with evidence that pY816 can inhibit PLCg1 activation in vitro and in vivo led us to ask whether systemic administration of pY816 exerted antiseizure effects in the KA model. Toward this end, either pY816 or Scr was administered (i.v.) prior to KA infusion and both EEG and behavioral seizures were monitored for 45 min ( Figure S2E ). To optimize the effects, we asked how varying doses and intervals of pY816 administration affected seizures evoked by KA. Compared to control peptide, infusion of pY816 reduced electrographic and convulsive motor seizures in a dose-and time-dependent manner; inhibition approximating 90% was obtained with 10 mg/kg infused 6 hr prior to KA ( Figures 3E-3H and S2F-S2I). Inhibition was evident as early as 10 min following i.v. infusion and inhibition of 50%-90% persisted for 24 hr, returning to control levels by 72 hr ( Figures 3G, 3H , S2H, and S2I). Together, these results demonstrate that treatment with pY816 prior to infusion of KA inhibits the prolonged seizures induced by KA in a dose-and time-dependent manner.
pY816 Peptide Prevents SE-Induced Epilepsy Usefulness of a preventive agent in a clinical setting requires it to be effective when administered after the SE. In the experiments described above, pY816 was administered prior to induction of SE by microinfusion of KA and suppressed the evoked seizures (i.e., anticonvulsant). A distinct question is whether administration of pY816 after chemoconvulsant-evoked SE prevents the resulting epilepsy (i.e., anti-epileptogenic). Prior to addressing this issue, we asked whether the neuroprotective effects of TrkB signaling are inhibited by treatment with pY816 administered after SE ( Figure 4A ). As observed previously ( Figures 1B and 1C) , SE led to destruction of CA3 and CA1 pyramidal cells as detected by FJC staining in sections from animals treated with Scr control peptide ( Figure 4B ). In contrast to inhibition of TrkB kinase, similar numbers of FJC-stained neurons were detected in animals treated with pY816 ( Figure 4B ), demonstrating that pY816 did not interfere with the neuroprotective effects of endogenous TrkB signaling.
We next sought to understand the time course of SE-induced activation of PLCg1, the idea being that a critical period of enhanced activation after prolonged seizures may define a therapeutic window during which inhibition of TrkB-PLCg1 signaling may prevent TLE. An episode of prolonged seizures induced a 2-to 3-fold increase of PLCg1 activation that was maximal during the first 24 hr and returned to normal by 72 hr ( Figure 4C ). Importantly, injection of pY816 after the episode of SE inhibited PLCg1 activation in a dose-dependent manner, inhibition approximating 75% with doses of 10 and 20 mg/kg ( Figure 4D ).
Next, we asked whether treatment with pY816 (10 mg/kg, i.v.) initiated after termination of SE with diazepam and repeated 24 and 48 hr thereafter prevented SE-induced epilepsy. Spontaneous seizures were detected using continuous video-EEG recordings during days 1-14 and days 29-42 after SE ( Figures  4E-4H ). Preventive effects of pY816 were evident during days 1-14 ( Figures 4G and 4H) . The latency to the onset of the first spontaneous seizure was delayed in pY816-treated animals compared to controls ( Figure 4G, top) . The initial spontaneous seizure was observed in 5 of 8 control animals within 3 days after prolonged seizures, whereas only a single pY816-infused animal exhibited a seizure in this interval. A striking reduction (86%) in the number of spontaneous seizures was observed in pY816 compared to Scr control animals during the 2 weeks immediately after SE (Figures 4G and 4H) . Additional video-EEG recordings were conducted during a 2-week period (days 29-42) initiated approximately 4 weeks after the last dose of pY816. Once again, a marked reduction (90%) in the number of spontaneous seizures was observed in pY816 compared to Scr control animals ( Figures 4G and 4H) . Among the eight animals treated with pY816, two exhibited no seizures and the remaining six animals exhibited only 1-3 seizures. By contrast, control animals exhibited 7-36 spontaneous recurrent seizures during this same interval ( Figures 4G and 4H) . Importantly, hippocampal damage, a pathological hallmark of TLE, was attenuated by pY816 treatment when assessed months after SE ( Figures S4A and S4B) .
Patients with epilepsy commonly exhibit anxiety disorders and anxiety-like behavior has been identified in the current model and was found to be prevented by transient inhibition of TrkB kinase commencing after SE (Liu et al., 2013) . We therefore asked whether this behavioral abnormality induced by SE can also be prevented by treatment with pY816. After completion of video-EEG recording during days 29-42, anxiety-like behavior was assessed using the light-dark emergence test (Bourin and Hascoë t, 2003) . In comparison to controls, mice undergoing SE followed by treatment with Scr exhibited a prolonged latency to enter the lighted compartment and spent less time in the lighted compartment ( Figures 4I and 4J) . By comparison to the Scr controls, mice undergoing SE followed by treatment with pY816 exhibited a significantly reduced latency to enter the lighted compartment and spent increased time in the lighted compartment ( Figures 4I and 4J) . Similarities in locomotor activity in an open field between two groups undergoing SE excluded differences in spontaneous activity as a confounding variable in the light-dark emergence results (data not shown). Collectively, these results demonstrate that treatment with pY816 for 3 days commencing after SE prevents SE-induced anxiety-like behavior as assessed by the light-dark emergence test.
Meaningful interpretation of the beneficial effects of pY816 treatment requires that the insult of SE be similar in the Scr control and pY816 groups. Behavioral and EEG features of the SE prior to treatment with Scr or pY816 revealed similarity of the insult in the two groups ( Figures S4C-S4E) . The anticonvulsant effects of pY816 when administered prior to SE raised the question as to whether treatment with pY816 administered after diazepam might suppress seizures and thereby minimize the SE insult. Detailed behavioral and EEG analyses for 48 hr after SE, including visual review by blinded reviewers (Figures 4G, top two rows, S4F, and S4G) and computerized measures of EEG power ( Figure S4H ) revealed no detectable anticonvulsant effects of pY816 when administered following diazepam.
DISCUSSION
Previous work utilizing a chemical-genetic approach revealed that transient inhibition of the receptor tyrosine kinase, TrkB, prevented epilepsy and anxiety-like disorder caused by a brief episode of SE (Liu et al., 2013) . Here we sought an inhibitor of TrkB signaling for prevention of epilepsy caused by SE. We used genetically modified mice and a novel biologic together with biochemical and electrophysiological methods in studies of an animal model. Global inhibition of TrkB signaling by targeting its kinase activity exacerbated neuronal death induced by SE assessed 1 day afterward, this untoward consequence leading us to seek a TrkB downstream signaling pathway promoting epilepsy. A combination of genetic approaches and a novel biologic, pY816, revealed PLCg1 to be the dominant signaling effector by which SE-induced TrkB activation promotes its epileptogenic consequences.
Clinical observations together with studies of animal models support the conclusion that an episode of SE contributes to the emergence of severe TLE years later (Annegers et al., 1987; Pitkä nen, 2010; Tsai et al., 2009 ). The seizure-free latent period provides a therapeutic window for intervention aimed at preventing development of TLE. The transiently enhanced activation of PLCg1 induced by SE in the current model largely (I and J) Anxiety-like behavior assessed by latency to enter light-compartment (I) and by time spent in lighted compartment (J). Mice undergoing infusion of PBS into amygdala served as controls (Con, n = 7). Data are presented from individual animals as well as mean (H) or as mean ± SEM and analyzed using Student's t test in (B) and (H) or two-way ANOVA with post hoc Bonferroni's test in (C), (D), (I), and (J). n.s. no significant difference, *p < 0.05, **p < 0.01, ***p < 0.001. preceded onset of recurrent seizures (Figures 4C and 4G, top left) . This provided a window of opportunity during which to intervene with pY816. Notably, only three doses of pY816 were administered after SE, the last of which was given 48 hr after the insult. The inhibition of spontaneous recurrent seizures assessed 4-5 weeks after the last treatment is not likely due to residual pY816 because the antiseizure effects of pY816 persisted less than 3 days after treatment ( Figures 3G, 3H, S2H , and S2I). The likelihood that pY816 will be effective in additional models of SE-induced TLE is strengthened by the fact that activation of TrkB and PLCg1 is detected in other SE models (He et al., 2010) . Whether TrkB signaling promotes epileptogenesis following other insults such as stroke or trauma is uncertain. The prevention of SE-induced abnormalities in the light-dark emergence test raises the possibility that pY816 may also exert anti-anxiogenic effects, a possibility warranting study with additional tests of anxiety-like behavior.
The diversity of diseases caused by excessive RTK signaling led to development of inhibitors, more than a dozen of which are in current clinical use (Lemmon and Schlessinger, 2010) . These are either small molecules that target the cytoplasmic kinase domain or monoclonal antibodies that target the extracellular domain, limiting ligand-mediated activation. While clearly useful, one limitation is that global inhibition of RTK signaling may have both desirable and undesirable consequences. Our studies reveal an undesirable consequence of global inhibition of TrkB kinase signaling, namely exacerbation of neuronal destruction detected 1 day after SE. This adds to prior work revealing neuroprotective effects of TrkB signaling, both in vitro and in vivo (Alcá ntara et al., 1997; Atwal et al., 2000; Nagahara et al., 2009; Wu and Pardridge, 1999) , an effect likely mediated by signaling downstream of Y515 of TrkB (Atwal et al., 2000) . This untoward consequence of global inhibition of TrkB signaling led us to identify PLCg1 as the key downstream signaling effector mediating the unwanted consequences of TrkB activation and design of a peptide to selectively inhibit the disease-causing pathway. The mechanism by which the peptide exerts its beneficial effects likely involves its binding an SH2 domain of PLCg1 ( Figure S3A ), thereby preventing the binding to and activation of PLCg1 by TrkB. This underlies the selectivity of pY816-mediated inhibition of PLCg1 and its downstream activation of CaMKII (Blanquet and Lamour, 1997; Minichiello et al., 2002) relative to p-Akt, p-S6 kinase, and p-ERK in vivo ( Figure 3C ). Among diverse RTKs, the variation of sequences flanking a core phosphotyrosine binding motif that binds the SH2 domain of a protein such as PLCg1 may result in different binding affinities of different RTKs for the SH2 domain containing protein (Koch et al., 1991; Songyang et al., 1993) . While pY816 may inhibit the interaction of PLCg1 with other RTKs in addition to TrkB, we provide evidence that TrkB is the principal RTK promoting PLCg1 activation following SE in this model ( Figure S3B) . Importantly, the limited duration of treatment with pY816 required for its beneficial effects is likely to minimize untoward consequences of limiting activation of PLCg1 by TrkB or other RTKs.
To the best of our knowledge, the strategy of treating a disease model in vivo by uncoupling an RTK from a signal transducer has not been successfully implemented. One reason may lie in the many tyrosine autophosphorylation sites within the cytoplasmic domain of an RTK such as the epidermal growth factor receptor (Lemmon and Schlessinger, 2010) , each of which can recruit different SH2 and PTB domain-containing adaptor proteins, the redundancy perhaps precluding inhibition of a single signaling pathway by disrupting a single point of contact of the RTK with an effector. By contrast, the relative paucity of identified tyrosine autophosphorylation sites within the cytoplasmic domain of TrkB (Huang and Reichardt, 2003) may reduce redundancy and enhance the feasibility of this strategy for TrkB and hopefully additional RTKs. Peptide inhibitors of protein-protein interactions provide an attractive option both because of their size (pY816 is 3,167 daltons) and because available knowledge of structural components required for the interaction of the RTK and the effector facilitates design. Importantly, the sequence of pY816 is identical in mouse and human, raising the possibility that pY816 itself or a derivative thereof may provide a therapeutic for prevention of TLE caused by SE in humans.
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